European Drugmakers Say They Are Losing Ground to US and Chinese Rivals

European pharmaceutical leaders urged governments to treat medicines as strategic infrastructure, warning of lost competitiveness against US and Chinese rivals due to investment gaps and regulatory delays. Nearly half of new therapies failed to reach European patients recently.